Overview

Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment

Status:
Not yet recruiting
Trial end date:
2023-10-13
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess how fast IBI362 gets into the blood stream and how long it takes the body to remove it in participants with impaired kidney function compared to healthy participants.
Phase:
Phase 1
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.